Global Newborn Screening Market to grow with a CAGR of 7.37%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Newborn Screening Market.
According
to TechSci Research report, “Global Newborn Screening Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Newborn Screening
Market has valued at USD 801.07 million in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 7.37% by 2028. This can be due to collaborations and partnerships
among leading companies with a diverse approach to merge the expertise of
individual companies and to strengthen their position in the market.
Expanded
screening panels is a significant driver for the global newborn screening
market. Expanded screening panels include tests for a more extensive array of
genetic, metabolic, and congenital disorders. This enables the early detection
of a broader range of conditions in newborns, some of which may not present
symptoms immediately. Identifying and diagnosing a wider spectrum of conditions
in newborns allows for earlier intervention and treatment. This can
significantly improve the long-term health outcomes for affected infants,
potentially preventing severe complications and developmental delays. For some
conditions, early detection through expanded screening panels can lead to
preventive measures or lifestyle changes that reduce the severity of the
condition or prevent it altogether. For example, dietary modifications can be
initiated for metabolic disorders. Expanded panels contribute to comprehensive
healthcare for newborns, addressing a more extensive set of potential health
concerns. This aligns with the concept of personalized and precision medicine,
where healthcare is tailored to individual needs.
Browse
over XX market data Figures and spread through 110
Pages and an in-depth TOC on " Global Newborn Screening Market”
The
newborn screening test is used to identify diseases that can be dangerous or
fatal to infants and have a negative effect on their long-term health. The
newborn screening test (CH) can identify about 30 metabolic and genetic
conditions, including galactosemia (GAL), phenylketonuria (PKU), sickle cell
anaemia, and congenital hypothyroidism. A newborn screening exam may also
include hearing tests, pulse oximetry, and blood testing. These screening exams
enable medical professionals to identify and address issues that affect a
baby's normal growth and development.
In
August 2022, At the AMTZ Campus in Vishakhapatnam, Trivitron Healthcare opened
a centre of excellence with cutting-edge R&D and production facilities.
Prof. Ajay Kumar Sood, Principal Scientific Advisor to the Government of India,
and Prof. (Dr.) Balram Bhargava, Former Director General, Indian Council of
Medical Research, both attended the launch ceremony. The facility includes a
cell culture and analytical lab, an Advanced Genomics and Molecular Diagnostics
facility for creating kits and reagents for Next Generation Sequencing (NGS),
Oligonucleotide Synthesis (synthesis of custom primers and Taq Man Chemistry
dual labelled probes), Protein Chemistry, and Next Generation Sequencing (NGS).
The business intends to produce all the raw ingredients and parts for molecular
diagnostics, NGS, and NBS internally using cutting-edge research methods and
protocols.
Public
perception and stigma can pose challenges in the global newborn screening
market. Many parents and caregivers may not fully understand the purpose and
benefits of newborn screening, leading to misconceptions or hesitancy regarding
the tests. Parents may be apprehensive about the possibility of their newborn
receiving a positive screening result, as it could indicate the presence of a
genetic or metabolic disorder. This fear can lead to avoidance of screening or
reluctance to follow up on positive results. Some genetic and metabolic
disorders screened for in newborns may carry stigmas or misconceptions.
Families may worry about social stigmatization if their child is diagnosed with
one of these conditions. Receiving a positive result for a newborn screening
test can be emotionally challenging for parents. It may necessitate difficult
decisions regarding treatment, quality of life, and family planning. Concerns
about genetic discrimination, such as discrimination in employment or
insurance, can influence parental decisions related to newborn screening.
Global Newborn Screening Market segmentation is
based on Technology,
Test Type, End User, and Region.
Based on Technology, Global Newborn Screening Market
is segmented into Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based
Assays, DNA Assays, and Other Technologies. Tandem Mass Spectrometry
(MS/MS) is a powerful analytical technique used in chemistry, biochemistry, and
various fields of science to identify and quantify the chemical composition of
complex mixtures, especially molecules like proteins, peptides, and
metabolites. It involves the use of two sequential mass spectrometry stages
(hence the term "tandem") to provide more detailed and accurate
information about the composition of a sample. Identifying and characterizing
proteins and peptides, including post-translational modifications. Profiling
and quantifying metabolites in biological samples to understand metabolic
pathways and disease biomarkers. Analyzing complex lipid mixtures in biological
samples to study lipid metabolism and lipid-related diseases. Quality control
and analysis of pharmaceutical compounds and formulations. Detecting and
quantifying environmental pollutants and contaminants.
Based on Region, North America dominated the Global Newborn Screening Market.
North America boasts a well-developed healthcare infrastructure with access to
state-of-the-art diagnostic technologies and medical facilities. This
infrastructure supports the implementation of comprehensive newborn screening
programs. Many North American countries, including the United States and
Canada, have robust government-funded healthcare systems that include newborn
screening as part of routine healthcare services. These programs are
well-supported and mandated by public health policies. Many North American
newborn screening programs offer extensive screening panels that cover a wide
range of genetic, metabolic, and congenital disorders. These comprehensive
panels are supported by robust laboratory infrastructure.
Asia-pacific region to fastest growth in the Global Newborn
Screening Market. APAC is the most populous region in the world, and it has a
significantly high birth rate. The sheer volume of newborns in the region
creates a substantial demand for newborn screening services. Awareness of
healthcare and the importance of early disease detection is increasing across
APAC countries. Parents and healthcare providers are becoming more conscious of
the benefits of newborn screening in preventing and managing congenital and
genetic disorders. Several countries in the APAC region have launched or
expanded government-supported newborn screening programs as part of their
public health initiatives. These programs aim to provide universal access to
screening services. Rapidly developing economies in APAC, such as China and
India, are investing in healthcare infrastructure, including newborn screening
facilities and technologies. The growing middle-class population in these
countries is also driving demand for quality healthcare services.
Some of the major companies
operating in the Global Newborn Screening Market include:
- Bio-Rad
Laboratories Inc.
- GE
Healthcare
- Masimo
Corporation
- Medtronic
Inc.
- Natus
Medical Incorporated
- PerkinElmer
Inc.
- Trivitron
Healthcare
- ZenTech
SA
- Demant
A/S
- Thermo
Fisher Scientific
- Hill-Rom
Holdings Inc.
Download Free Sample Report
Customers can also request 10% free customization on this report.
“Certain areas, particularly in North America, are
projected to exert significant demand for Newborn Screening. The growth in the
competitive landscape and the presence of well-established companies in the
market, committed to enhance the overall wellbeing of people each year, are
expected to contribute to a remarkable growth of the Global Newborn Screening
Market in the forecast period," said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based Global management consulting firm.
Newborn
Screening Market - Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028 Segmented by Technology (Tandem Mass Spectrometry, Pulse Oximetry,
Enzyme Based Assays, DNA Assays, and Other Technologies), By Test Type (Dried
Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), and
Other Test Types), By End User (Hospitals, Diagnostic Centers, and Other End
Users), and By Region, Competition evaluated the future growth potential of Global Newborn
Screening Market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide innovative market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Newborn Screening Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com